HONG KONG – South Korean biotech company Qurient Co. Ltd. has inked a joint venture (JV) foundation deal involving Germany's Max Planck Society (MPG), of Munich, and Lead Discovery Center GmbH (LDC) in Dortmund, as well as the 1988 Nobel laureate and biochemist Robert Huber. Read More
HONG KONG – One of South Korea's biggest pharmaceutical companies by market capitalization, GC Pharma Corp., based in Yong-in, Gyeonggi-do, and the Cambridge, Mass.-based U.S. biotech Vaxess Technologies Inc., have partnered to globally commercialize a flu vaccine patch based on Vaxess' Mimix Smart Release Patch technology. Read More
SAN FRANCISCO – At what BIO CEO and President Jim Greenwood called a "Dickensian moment in the history of biotechnology – arguably the best of times and the worst of times" for U.S. industry players, new rules piloted by the Committee on Foreign Investment in the U.S. (CFIUS) have made things even more challenging. Read More
HONG KONG – South Korean biopharma Virocure Inc., based in Seoul, recently founded a local corporation in Brisbane, Australia. The new company, Virocure Australia Pty Ltd., will facilitate a phase I trial of the experimental cancer drug RC-402 in Australia. Read More
Australian scientists have discovered promising new candidate analgesic molecules derived from a Penicillium fungus, which represents a promising resource for the development of safer new analgesics, they reported in the Oct. 14, 2019, edition of Proceedings of the National Academy of Sciences. Read More
BEIJING – Shanghai-based Visen Pharmaceuticals is pushing its long-acting growth hormone therapy, which is also the first of its kind in China, one step closer to the NDA-stage after receiving clearance from Chinese regulators this week to start a phase III trial. Read More
BEIJING – Hightide Therapeutics Inc., of Shenzhen, China, and Rockville, Md., said it finished the enrollment in phase IIa trials for its lead asset, HTD-1801, which is a potential first-in-class new molecular entity for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH). Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific. Read More